Tadalafil
Product Images NDC 68071-2613

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 68071-2613). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2613 3)

Label of Tadalafil 10 mg tablets from NuCare Pharmaceuticals, Inc. The bottle contains 30 tablets. The label includes the product NDC 68071-2613-3, manufacturer Aljanta Pharma Limited, Mumbai, India. It shows warnings, storage instructions, and barcodes, along with batch and expiration data placeholders. The label indicates Rx only and advises patient instructions for dosing frequency.*

FDA Label Image

Figure8 (Tadalafil Fig8)

This line graph depicts the change from baseline in IPSS total score over a 12-week treatment period comparing Tadalafil 5 mg and placebo. The x-axis represents treatment duration in weeks, while the y-axis shows the change in score. The Tadalafil 5 mg line shows a greater decrease over time compared to placebo, with a significant difference at 12 weeks (p<0.01).*

FDA Label Image

Figure1 (Tadalafil Figure1)

A set of four line graphs showing the effect of Tadalafil compared to placebo on standing and supine systolic and diastolic blood pressure over time. Each graph plots the difference in blood pressure (mmHg) on the y-axis against time in hours on the x-axis, with data points connected by lines and error bars for variability.*

FDA Label Image

Figure2 (Tadalafil Figure2)

Two line graphs displaying changes in systolic blood pressure over 24 hours post-dose. The top graph shows standing systolic BP in mmHg, and the bottom graph shows supine systolic BP in mmHg. Both compare tadalafil 20 mg with doxazosin 8 mg versus placebo with doxazosin 8 mg.*

FDA Label Image

Figure3 (Tadalafil Figure3)

A line graph depicting systolic blood pressure changes (mmHg) over 12 hours after administration of tadalafil or placebo, combined with doxazosin. The x-axis represents time after administration, and the y-axis shows systolic blood pressure changes. Four conditions are compared: tadalafil 20 mg at 08:00 and 20:00 with 8 mg qd doxazosin at 08:00, and placebo at the same times with doxazosin.*

FDA Label Image

Figure4 (Tadalafil Figure4)

A line graph depicting plasma tadalafil concentration (µg/L) over time (hours). The graph compares three dosing regimens: single 20-mg dose, single 5-mg dose, and once-daily 5-mg dose following 5 consecutive days of administration, showing their respective concentration profiles with error bars.*

FDA Label Image

Figure5 (Tadalafil Figure5)

A line graph showing the change from baseline in I-PSS Total Score over 12 weeks of treatment. It compares Tadalafil 5 mg to placebo, with distinct markers for each. The graph indicates a greater reduction in score over time for Tadalafil 5 mg compared to placebo, with statistical significance noted (p<0.01). The x-axis represents duration of treatment in weeks, and the y-axis shows change from baseline in total score.*

FDA Label Image

Figure6 (Tadalafil Figure6)

A line graph comparing the change from baseline in IIEF (International Index of Erectile Function) Erectile Function Domain Score between Tadalafil 5 mg and placebo over 12 weeks of treatment. The graph shows data points at 0, 1, 4, and 12 weeks, with Tadalafil 5 mg demonstrating greater score improvement than placebo, with statistical significance indicated at some points (p<0.01).*

FDA Label Image

Figure7 (Tadalafil Figure7)

A line graph showing the least-squares mean change from baseline over 26 weeks of therapy. It compares Tadalafil/Finasteride and Placebo/Finasteride groups, with data points at weeks 0, 4, 12, and 26. Statistically significant differences are noted at certain time points.*

FDA Label Image

Structure (Tadalafil Structure)

Chemical structure diagram of Tadalafil, showing the arrangement of its atoms and bonds as submitted in the FDA Structured Product Labeling for NuCare Pharmaceuticals, Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.